Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (NYSE: IQV) is frequently in the news as a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. News coverage about IQVIA highlights how the company combines high-quality health data, Healthcare-grade AI®, advanced analytics and technology to support clinical development and commercial decision-making.
On this page, readers can follow IQVIA news related to clinical research initiatives, technology launches and strategic partnerships. Recent announcements include a strategic collaboration with Amazon Web Services, under which AWS has been named IQVIA’s Preferred Agentic Cloud Provider to power a next-generation AI platform. Other news items describe the launch of IQVIA’s Clinical Trial Financial Suite, an AI-enabled platform for managing financial aspects of clinical trials, and partnerships with organizations such as Veeva Systems.
IQVIA news also covers topics such as quarterly financial results, leadership and board changes, awards for site relationships in clinical research and the expansion of clinical research networks. For example, the company reports on its Research & Development Solutions bookings and backlog, as well as its recognition with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication.
Investors, researchers and industry professionals can use this news feed to monitor developments in IQVIA’s clinical research services, healthcare analytics capabilities, AI initiatives and collaborations across the life sciences ecosystem. Regularly reviewing IQVIA news can provide insight into how the company is applying data, analytics and technology to support the development and commercialization of medical treatments.
Summary not available.
IQVIA (NYSE:IQV) has announced a collaboration with Servier to enhance its R&D clinical development processes through the SCORE program. This initiative aims to transform Servier's clinical trial applications and improve patient outcomes by utilizing optimized processes, data-driven insights, and innovative technology. Over the next two years, IQVIA will implement a robust program that leverages its expertise in R&D consulting, digital transformation, and technology solutions. The partnership is poised to address unmet medical needs and support Servier's ambitious growth plans.
IQVIA (NYSE: IQV) announced its support for the Real World Evidence Leadership Forum, uniting senior RWE executives from 18 pharmaceutical companies. This non-competitive group aims to address RWE challenges and enhance patient outcomes globally. Underlining the significance of real-world data, Dan Simpson of IQVIA stated that establishing trust in data usage is crucial. The forum's immediate focus includes fostering collaborative relationships between pharma and healthcare, promoting publications on trusted partnerships, and meeting biannually to tackle industry issues.
IQVIA announced that Zentiva is implementing its Orchestrated Customer Engagement (OCE) platform in 12 major markets. This partnership aims to enhance Zentiva's commercial operations and customer interactions. OCE will facilitate optimization of field processes and multi-channel marketing through AI/ML capabilities, benefiting sales and marketing teams. Paul Geymayer from Zentiva emphasized the importance of digitally enabling their teams to foster growth and efficiency.
IQVIA Holdings reported third-quarter 2020 revenue of $2,786 million, a slight increase of 0.6% year-over-year, with Technology & Analytics Solutions (TAS) revenue growing 10.2%. However, Research & Development Solutions (R&DS) revenue fell 4.5%, and Contract Sales & Medical Solutions (CSMS) dropped 13.9%. Adjusted EBITDA reached $604 million, up 1.9%. The company raised its 2020 revenue guidance to $11,100 - $11,250 million and provided a strong outlook for 2021, anticipating revenue between $12,300 million and $12,600 million.
IQVIA (NYSE: IQV) announces a partnership with the U.S. FDA to analyze data from its CARE Project COVID-19 registry. This project aims to gather insights on COVID-19 symptoms experienced by U.S. residents, regardless of diagnosis. Launched in April 2020, over 20,000 participants have enrolled, providing data on symptom severity and potential effects of medications and supplements. Nancy Dreyer, Chief Scientific Officer, emphasizes the project's focus on community-level insights and the role of various preventive agents, leveraging IQVIA's CORE technology for rapid analytics.
IQVIA Holdings Inc. (NYSE: IQV) will release its third-quarter financial results on October 20, 2020, before the market opens. Management will host a conference call at 9:00 a.m. ET on the same day, which can be accessed via the IQVIA Investor Relations website. Registration is required for participation, and a replay will be available shortly after the event. IQVIA specializes in analytics and technology solutions for the life sciences sector, employing around 67,000 individuals globally.